Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc develops and manufactures therapeutic medical devices and healthcare technology for chronic diseases and procedural care. Its news commonly covers regulatory clearances and CE marks, product launches, clinical data, acquisitions, and financial results across cardiovascular, cardiac rhythm management, cranial and spinal technologies, surgical navigation, robotics, and ablation systems.
Recent company updates include the Stealth AXiS™ surgical system for planning, navigation, and robotics; the Affera™ mapping and ablation system with Sphere-9™ and Sphere-360™ catheters; the OmniaSecure™ defibrillation lead; and the completed CathWorks acquisition, including the FFRangio® System for coronary artery disease assessment.
Medtronic (NYSE: MDT) announced that its board of directors approved a $0.72 cash dividend per ordinary share for the second quarter of fiscal year 2027. The dividend will be payable on October 16, 2026, to shareholders of record as of September 25, 2026. The company noted this quarterly dividend is consistent with the dividend increase announced in June 2026 and highlighted its inclusion in the S&P 500 Dividend Aristocrats index, reflecting 49 consecutive years of annual dividend increases.
Orchestra BioMed (Nasdaq: OBIO) reported second quarter 2026 results and updates on its pivotal cardiovascular programs. The BACKBEAT global pivotal trial of AVIM Therapy, conducted with Medtronic, is on track to reach 284 evaluable randomized patients by the end of Q3 2026, with primary endpoint data presentation targeted for Q2 2027. The Virtue SAB pivotal trial for coronary in-stent restenosis continues to progress with additional site activations and patient enrollment, and AVIM Therapy received a second FDA Breakthrough Device Designation.
According to Orchestra BioMed, Q2 2026 cash, cash equivalents and marketable securities totaled $110.0 million, including $35 million in new strategic capital from Medtronic and Ligand, providing projected runway into Q4 2027. Q2 revenue was $0.1 million, research and development expenses were $16.6 million (up 20% year over year), selling, general and administrative expenses were $5.8 million (down 7%), and net loss attributable to common stockholders was $24.1 million, or ($0.38) per share. The company was added to the Russell 3000 and Russell 2000 indexes and plans an R&D Day on November 12, 2026, in New York City.
Medtronic (NYSE: MDT) announced an expanded CE Mark indication for its Affera™ Mapping and Ablation System with Sphere-9™ Catheter to treat ventricular arrhythmias, including ventricular tachycardia (VT) and premature ventricular complexes (PVCs). Sphere-9 is the first all-in-one mapping and ablation, large-tip focal, dual-energy catheter CE marked for ventricular ablation.
The FDA has granted Breakthrough Device Designation for Sphere-9 for ventricular arrhythmias, providing an expedited U.S. regulatory pathway. Medtronic also reported that the Sphere VT pivotal trial, designed to support future U.S. approval for VT treatment, is now enrolling patients.
Medtronic (NYSE: MDT) will report financial results for its first quarter of fiscal year 2027, which ended on July 31, 2026, on Tuesday, September 1, 2026. A news release will be issued at 5:45 a.m. CT, followed by a video webcast discussing the results at 6:45 a.m. CT, both accessible through Medtronic’s news and investor relations websites.
Medtronic (NYSE: MDT) has completed the $650 million cash acquisition of SPR Therapeutics, adding SPR’s category-defining SPRINT® peripheral nerve stimulation (PNS) technology to Medtronic’s pain therapy portfolio. According to Medtronic, the deal advances its non-opioid, minimally invasive treatment offerings for both chronic and acute pain.
SPR’s FDA-cleared SPRINT PNS System delivers short-term, percutaneous neuromodulation over a 60-day period without a permanent implant. Pooled data from 13 studies show 60% of patients achieved at least a 50% pain reduction, responders averaged a 76% reduction, and all patients showed a 56% reduction in pain intensity. Medtronic expects the transaction to be minimally dilutive to adjusted EPS in FY27 and neutral to accretive thereafter, aligning with its strategy to pursue high‑growth, complementary pain therapies.
Medtronic (NYSE: MDT) completed its $550 million acquisition of Scientia Vascular, a Salt Lake City-based neurovascular access device company. Scientia’s guidewires and catheters are designed to improve navigability in complex cerebral anatomy and will integrate with Medtronic’s neurovascular portfolio.
The deal targets enhanced procedural efficiency in stroke and aneurysm care and aligns with Medtronic’s strategy to strengthen core businesses and pursue high-growth opportunities. The transaction is expected to be minimally dilutive to adjusted EPS in FY27 and accretive thereafter.
Medtronic (NYSE: MDT) announced multiple U.S. milestones for its Hugo™ robotic-assisted surgery (RAS) system, aimed at expanding into general and gynecologic surgery.
The company submitted 510(k)s for general and gynecologic indications and the LigaSure™ RAS Maryland instrument, received 510(k) clearance for ProGrip™ Advanced mesh for robotic ventral hernia repair, and completed enrollment in the Embrace Gynecology IDE study.
Medtronic (NYSE: MDT) announced strategic investments in two ICE catheter developers, Beluga Medical in California and CardioACC in Shenzhen, China, to support future expansion of its cardiac ablation portfolio.
Medtronic plans to integrate intracardiac echocardiography into its Affera mapping and ablation system to enhance electrophysiology workflows and strengthen the Affera ecosystem.
Medtronic (NYSE: MDT) reported Q4 FY26 revenue of $9.8 billion, up 9.9% reported and 6.6% organic, with non-GAAP EPS of $1.55. FY26 revenue reached $36.4 billion, up 8.4% reported and 5.8% organic, and GAAP EPS was $3.73, up 3.3%.
Cash from operations was $7.3 billion and free cash flow $5.4 billion. The quarterly dividend was raised to $0.72 per share, the 49th consecutive annual increase. FY27 guidance calls for 6.75%-7.25% organic revenue growth and non-GAAP EPS of $5.90-$6.00.
morph launched a physically intelligent soft robotics cells platform that embeds sensing and adaptive control into deformable materials, enabling real‑time changes in shape and stiffness for safer human interaction.
Backed by investors including 8VC and Pharrell Williams, morph targets athletic performance, injury prevention, mobility support, and future applications in healthcare, automotive, and industrial safety via a B2B partnership model.